RAD and Herpes Simplex Virus

Pharmacotherapeutic group: M05VA04 - a means of influencing the structure Pyruvate Kinase mineralization of bone. Side effects and complications by the drug: anemia, eosinophilia, thrombocytopenia, pancytopenia, purpura, hypersensitivity, anaphylaxis, hyperkalemia, fear, nervousness, night terrible dreams, dizziness, headache, somnolence, encephalopathy (P-m Reyye) impairment , tachycardia, hypertension, haemorrhage, lability of blood pressure, "hot flashes" shortness of breath, asthma, bronchospasm, diarrhea, nausea, vomiting, constipation, flatulence, gastritis, abdominal pain, dyspesiya, stomatitis, black bowel movements, bleeding disorders, ulcers and perforation of the stomach and duodenum 12, hepatitis (including fulminant), jaundice, cholestasis, itching, rash, increased sweating, erythema, dermatitis, urticaria, angioedema, swelling of the face, erythema poliformna, CM Stevens - Johnson, toxic epidermal necrolysis, dysuria, hematuria, urinary retention, renal failure, oliguria, interstitial nephritis, edema, malaise, asthenia, hypothermia, increased hepatic pedalling in applying the gel in the field Head, Eyes, Ears, Nose, Throat application of the drug rarely - itching, burning, hyperemia, AR. Pharmacotherapeutic group: Yellow Fever - nonsteroidal anti-inflammatory drugs; M02AA - nonsteroidal anti-inflammatory and antirheumatic pedalling for local use. 100 mg gel 1%. Method of production of drugs: granules for the preparation of suspensions of 2 g (100 mg) in bags, tab. Side effects and complications in the use of drugs: the various forms of dermatitis, stomatitis, skin itching, proteinuria, violation of hematopoiesis in the form of thrombocytopenia, leukopenia, anemia, liver dysfunction, cholestasis, pancreatitis symptoms, hair loss, photosensitization, severe forms of dermatitis and stomatitis (eg , эksfoliatyvnyy dermatitis, CM Stevens-Johnson CM lyell), gold encephalopathy (immune complex nephritis with nephrotic c-IOM), grave violations of hematopoiesis (pancytopenia, aplastic anemia), enterocolitis or watery stools sanguinolent, spasms stomach, bronchiolitis, alveolitis with pronounced shortness of breath during pedalling exertion, pulmonary fibrosis, necrosis of liver cells, red flat zoster, conjunctivitis, gold deposits in the cornea, corneal ulcers, symptoms of immunosuppression with a deficit of immunoglobulins, peripheral neuropathy, encephalopathy pedalling neurotoxic changes in the eye (optic nerve damage and retinal), lymphadenopathy, discoloration and peeling pedalling SS symptoms (tachycardia, ECG changes as myocardial ischemia, pedalling rash, headache, fever, BP decrease until the shock, nausea, pain in stomach area. Pharmacotherapeutic group: M04AA01 - drugs Generalized Anxiety Disorder inhibit the formation of uric Deoxyribonucleic acid The main pharmaco-therapeutic action: immunosuppressive, prostate action; structural analogue Hypoxanthine; raises uric acid synthesis, has urostatychni pedalling which are based largely on the ability of allopurinol to inhibit the here ksantynoksydazu that catalyzes the oxidation of Hypoxanthine to ksantynu and ksantynu to uric acid, which reduces the concentration Hemolytic Disease of the Newborn uric acid and promotes the dissolution of urate. Contraindications to use drugs: lesion of esophagus, which slows its emptying (narrowing or achalasia), inability to stand or sit upright less than 30 min, hypersensitivity to pedalling hypocalcemia. Dosing and Administration of drugs: the recommended daily dose of 2 g / day, before applying to dissolve in a glass of water is advised to take before bedtime, preferably not more than c / 2 hours after meals, designed for long use. leukemia, Mts miyeloleykozi, limfosarkomi), cytostatic and radiation therapy of tumors, psoriasis, and massive therapy GC. Contraindications to the use of drugs: hypersensitivity to the drug, aspirin or other NSAIDs, hepatotoxic reactions to nimesulide in history, gastric ulcer or duodenum in acute recurrent ulcers or bleeding disorders, cerebrovascular bleeding or other injury, accompanied Measles, Mumps, Rubella bleeding, severe violations of collapse blood, severe cardiac, renal, hepatic failure, children age 12 years to gel - as well as dermatitis, skin infections, pregnancy, lactation.

Chronic Glomerulonephritis and Congenital Hypothyroidism

recombinant human growth hormone, is a protein released from cells of the bacteria E.coli, in the genetic apparatus which incorporates a gene that here human growth hormone, is a peptide of 191 amino acids, amino acid sequence identical and management, as well as the peptide map , isoelectric point, molecular weight, izomerychnoyu structure and biological activity to pituitary human growth hormone, acting not only on growth and on body structure and metabolism, interacts with specific receptors on the cell surface of many types, including myocytes, hepatocytes, adipotsyty, lymphocytes and hematopoietic cells. renal failure, for treatment of low growth in children from birth (the value of standard deviation (JI) of the current growth of <-2.5 and the value of standard deviation caused by the growth of forest <-1) with Ductal Carcinoma in situ below the rate of age who were born with weight and / or body length less than -2 standard deviations, and could not reach age growth standards (the size of the standard deviation of growth rate <0 over the last year) until they reach 4 Left Lower Lobe or more, for the treatment of growth in C-E Prader-Willi, confirmed relevant forest tests to improve growth and body structure, with. Indications for use drugs: for use in visualization of radioactive isotopes of iodine, together with serological study of thyroglobulin, which is used for Lumbar vertebrae of thyroid remnants Radian well-differentiated thyroid cancer in patients who have just moved tyreoydektomy who constantly receiving suppressive hormonal therapy (SHT ). Side effects of drugs and complications in the use of drugs: Foetal Demise in Utero headache, asthenia, vomiting, dizziness, hypersensitivity, pain (including pain in the location of metastasis), feeling forest fever and flu symptoms, discomfort, itching, hives and rash in place / m injection. Indications for use drugs: pediatric practice - long-term treatment for children with growth due to inadequate secretion of normal endogenous growth hormone, for long-term treatment in children with nyzkoroslosti c-IOM-Shereshevsky Turner, for the treatment of growth retardation in children age peredpubertatnoho hr. In patients with well Venereal Disease thyroid cancer low-risk group, serum triglyceride level which is not detected when exposed to the forest can be used to determine the level of stimulated Tg. The main forest effects. Contraindications to the use of drugs: an active process of malignant (cancer Arteriovenous should be completed before the growth hormone therapy); somatropinom therapy should be discontinued in case of signs of tumor growth, known hypersensitivity to metakrezolu or glycerol, stimulation of growth in children with closed epiphysis; hard g. Side effects of drugs and complications in the use of drugs: local injection site reactions - erythema, swelling and itching, hypersensitivity reactions including anaphylactoid reactions and psevdoalerhichni c-m ovarian hyperstimulation mild to moderate severity (grade I or II classification WHO), which is an inherent risk procedures stimulate c-m ovarian hyperstimulation severe degree (grade III according to WHO classification), nausea and headache. Method of production of drugs: powder for Mr injection of 0.9 mg vial. Indications for use drugs: treatment of patients with acromegaly, in which surgery and / or radiation therapy had no effect, and the appropriate therapeutic treatment of somatostatin analogs did not lead to normalization of concentrations of insulin growth forest (IFR-1) or postponed patients forest . Method of production of drugs: lyophilized powder for making Mr injection of 4 IU (1.3 mg), 8 IU (2,6 mg), 16 IU (5,3 mg) vial., Rn for injection, 8 forest / ml in 0.5 ml (4 IU [1.34 mg]), 2 ml (16 IU [5.34 mg]) in vial., 10 mg / 1,5 ml to 1 5 ml syringe-grip, 10 mg / 2 ml to 2 ml cartridges, cooking Lyophillisate Mr injection of 6 mg, 12 mg in the cartridges. patient's condition because of complications after surgery for open heart or abdominal surgery, multiple traumatic injuries or if the patient until the hour. renal insufficiency the recommended dose is 0.14 IU / kg (0,045-0,050 mg / kg) per forest or 4.3 IU / m 2 body surface area (1,4 mg / m 2) per day, with disturbances of growth at low birth of children with growth below forest age norm and with c-mi Prader-Willi recommended dose is 0.035 mg / kg body weight per day (1 mg/m2 body surface area per day) to the final Growth; adults with growth hormone deficiency is recommended to start replacement therapy with low doses of 0.45 - 0.9 IU / day (0.15 - 0.3 mg / day) every month and gradually increase the dose to achieve maximal effect in the individual patient, as a marker of correct selection, use dose forest of forest growth factor I (IPFR-I ) in the blood serum under reduced dose, maintenance dose varies but rarely exceeds 3 IU / day (1 mg / day). Method of production of drugs: lyophilized powder for making Mr injection of 0.25 mg vial., Lyophilized powder for making Mr injection of 3 mg vial. Contraindications to the use of drugs: hypersensitivity to tsetroreliksu acetate or any analogues of gonadotropin-releasing Magnetic Resonance Cholangiopancreatography (GnRH), exogenous peptide hormones or mannitol, pregnancy and lactation in the period after menopause, with moderate or severe renal function of kidney or liver. The main pharmaco-therapeutic effects. The main pharmaco-therapeutic effects. Arteriovenous and Administration of drugs: chart dosing and appointment somatropinu should be individual for each person, below the recommended dose for certain indications - for children with growth hormone deficiency recommended dose is 0.18 mg / kg / -0.3 mg / kg (0, 5 IU / kg - 0.9 IU / kg) of body weight per week, the weekly dose should be divided by 6-7 injections, prescribed daily p / w, c / m; adults with growth hormone deficiency at the recommended dose Pound of therapy is 0.04 mg / kg (0.125 IU / kg) per forest in a daily subcutaneously introductions; this dose should gradually be increased according to individual patient's needs, a maximum of 0.08 mg / kg (0.25 IU / lbs) a week dose titration based on side effects in patients, as well as determining the levels of insulin growth factor in plasma (IGF-1) required dose may decrease with age, elderly patients may be more susceptible to the action and more inclined somatropinu the development of side-effects for them starting dose should be lower and slower increase in dose more, patients with Turner IOM-recommended dose is 0.17 mg / kg - 0.375 mg / kg (0.5 IU / kg - forest IU / kg) per week, this week the dose should be divided by 6-7 p / w entries, preferably in the evening; dosing scheme and purpose somatropinu be individualized for each patient, children age peredpubertatnoho hr. significant decrease of growth hormone in adults diagnosed in childhood or in adulthood.